Leading Biotech Selects Veeva Vault CRM Globally

Veeva Systems will provide its Vault CRM suite globally to Amgen, extending their long-standing life sciences technology collaboration.

Rhea-AI Summary

Veeva Systems (VEEV) announced that Amgen plans to deploy Veeva Vault CRM globally, expanding a collaboration that has lasted more than a decade.

Amgen’s chief information officer said the move to Vault CRM is expected to support faster, more agile delivery of new therapies to patients worldwide. Veeva’s president of commercial strategy described Vault CRM as an agentic commercial foundation to help Amgen reach millions of patients with medicines for difficult diseases.

Vault CRM is part of the Vault CRM Suite, which is described as enabling agentic commercial engagement with healthcare professionals and includes the Agentic Call Report to generate Commercial Evidence and identify hidden treatment barriers.

Market Context

Prior Vault CRM selection announcements for Biogen and Regeneron each accompanied a -0.64% 24-hour r...

Analysis

Prior Vault CRM selection announcements for Biogen and Regeneron each accompanied a -0.64% 24-hour reaction, providing directly comparable platform context for Amgen's global deployment; the pre-publication dataset does not include a post-headline reaction.

Key Figures

Collaboration duration: More than a decade

Collaboration duration

More than a decade

Veeva-Amgen collaboration

Historical Context

2 past events · Latest: Aug 25

2 events

1. Aug 25

   Vault CRM selection

   24h Move

   -0.6%

   Biogen committed to deploy Vault CRM globally as its commercial platform.

2. Aug 25

   Vault CRM selection

   24h Move

   -0.6%

   Regeneron committed to deploy Vault CRM globally across its commercial organization.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hcp, public benefit corporation, forward-looking statements, form 10-q

4 terms

hcp medical

"healthcare professionals (HCPs) to accelerate launch performance"

An HCP (healthcare professional) is a licensed medical practitioner—such as a doctor, nurse, pharmacist or clinician—who diagnoses, treats and advises patients. For investors, HCPs are important because their prescribing choices and treatment recommendations directly affect product sales and market uptake, acting like gatekeepers whose preferences and acceptance can determine a therapy’s commercial success and regulatory exposure.

public benefit corporation regulatory

"As a Public Benefit Corporation, Veeva is committed"

A public benefit corporation is a legal type of company that pledges to pursue a specific public good—such as environmental protection, worker welfare or community development—alongside earning profits for shareholders. Like a restaurant that promises to source local ingredients while still trying to turn a profit, this structure lets managers weigh social goals against financial returns, which can influence strategy, risk profile and investor expectations about how decisions are made.

forward-looking statements regulatory

"This release contains forward-looking statements regarding Veeva's products"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

form 10-q regulatory

"disclosed in our filing on Form 10-Q for the fiscal year"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Agentic CRM foundation to help accelerate the delivery of innovative medicines to patients worldwide

PLEASANTON, Calif., Sept. 15, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade.  

"Moving to Vault CRM will help accelerate our efforts to bring new therapies to patients globally with greater speed and agility," said Scott Skellenger, senior vice president and chief information officer at Amgen. "Veeva's deep understanding of life sciences, its continued focus on innovation, and our long-standing collaboration will help support Amgen in achieving these important goals."

"Vault CRM will provide the agentic commercial foundation to help Amgen deliver innovative medicines for some of the world's toughest diseases to millions of patients," said Matt Farrell, president, commercial strategy at Veeva. "We look forward to supporting Amgen as it launches important new therapies worldwide."

Vault CRM is part of the Vault CRM Suite, the technology foundation for agentic commercial, transforming how the industry engages with healthcare professionals (HCPs) to accelerate launch performance and improve patient outcomes. It includes the Agentic Call Report to generate Commercial Evidence and uncover previously hidden treatment barriers.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Maria Scurry Veeva Systems maria.scurry@veeva.com	Meera Lakhani-Patel Veeva Systems, Europe meera.lakhani-patel@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/leading-biotech-selects-veeva-vault-crm-globally-302878469.html

SOURCE Veeva Systems